Prognostic Significance of Serum Uric Acid and Gamma-Glutamyltransferase in Patients with Advanced Gastric Cancer

Figure 5

The calibration curve for predicting patient progression-free survival at (a) 6 months and (b) 1 year in the primary cohort and at (c) 6 months in the validation cohort. Nomogram-predicted probability of progression-free survival is plotted on the -axis; actual progression-free survival is plotted on the -axis.

(a)

(b)

(c)